GLYCOSAMINOGLYCAN POLYSULFURIC ACID (GAGPS) IN OSTEOARTHRITIS OF THE KNEE

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F95%3A%230000955" target="_blank" >RIV/00064190:_____/95:#0000955 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/S1063-4584(05)80034-2" target="_blank" >http://dx.doi.org/10.1016/S1063-4584(05)80034-2</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/S1063-4584(05)80034-2" target="_blank" >10.1016/S1063-4584(05)80034-2</a>

Jazyk výsledku

angličtina

Název v původním jazyce

GLYCOSAMINOGLYCAN POLYSULFURIC ACID (GAGPS) IN OSTEOARTHRITIS OF THE KNEE

Popis výsledku v původním jazyce

We studied the efficacy and tolerability of glycosaminoglycan polysulfuric acid (GAGPS) in 80 patients with osteoarthritis (OA) of the knee. Patients received two series of five intra-articular injections, at 1-week intervals, of 25 mg (0.5 ml) GAGPS into the knee in a double-blind, parallel, randomized, placebo-controlled trial. There was an immediate decrease in pain after the injections of 43% with GAGPS and 33% with placebo (P = 0.047) (Jezek pain index). Pain relief of GAGPS vs placebo was not different at other intervals (10, 14, 22, 26 weeks after start of treatment). At 6 weeks the Lequesne index decreased 20% after GAGPS and 9% after placebo (P = 0.17). At 10 weeks the Lequesne index decreased 24% after GAGPS and 13% after placebo (P = 0.20).The decrease in Lequesne index at 14 weeks was 31% after GAGPS and 15% after placebo (P = 0.06). The other measured parameters tended to be more favorably influenced by GAGPS than placebo. GAGPS was well tolerated, with associated mild ad

Název v anglickém jazyce

GLYCOSAMINOGLYCAN POLYSULFURIC ACID (GAGPS) IN OSTEOARTHRITIS OF THE KNEE

Popis výsledku anglicky

We studied the efficacy and tolerability of glycosaminoglycan polysulfuric acid (GAGPS) in 80 patients with osteoarthritis (OA) of the knee. Patients received two series of five intra-articular injections, at 1-week intervals, of 25 mg (0.5 ml) GAGPS into the knee in a double-blind, parallel, randomized, placebo-controlled trial. There was an immediate decrease in pain after the injections of 43% with GAGPS and 33% with placebo (P = 0.047) (Jezek pain index). Pain relief of GAGPS vs placebo was not different at other intervals (10, 14, 22, 26 weeks after start of treatment). At 6 weeks the Lequesne index decreased 20% after GAGPS and 9% after placebo (P = 0.17). At 10 weeks the Lequesne index decreased 24% after GAGPS and 13% after placebo (P = 0.20).The decrease in Lequesne index at 14 weeks was 31% after GAGPS and 15% after placebo (P = 0.06). The other measured parameters tended to be more favorably influenced by GAGPS than placebo. GAGPS was well tolerated, with associated mild ad

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FP - Ostatní lékařské obory

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

1995

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

OSTEOARTHRITIS AND CARTILAGE

ISSN

1063-4584

e-ISSN

—

Svazek periodika

3

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

8

Strana od-do

15-23

Kód UT WoS článku

A1995QW77400003

EID výsledku v databázi Scopus

—